Zosia Miedzybrodzka has been appointed an Officer of the Order of the British Empire (OBE) for her services to genetics ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

Zydus Lifesciences has partnered with US-based Myriad Genetics to bring advanced cancer risk and prognostic tests to India, aiming to boost personalized oncology care.

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

The 85-year-old singer says that his cancer was caught early and is "gone at the moment", and is calling for others to get tested.

Singer Sir Cliff Richard has shared his prostate cancer diagnosis experience and is calling for a UK-wide screening programme ...